Vaxart, operating as a clinical-stage biopharmaceutical company, does not have a static corporate net worth equivalent to a profitable manufacturing enterprise; instead, its financial valuation is represented by its public market capitalization. Depending on daily share price fluctuations and prevailing trading volumes, Vaxart's market capitalization typically spans tens of millions of dollars. Because early-stage biotechnology firms burn through capital funding expensive laboratory research, manufacturing scaling, and human clinical trials before commercializing any pharmaceutical products, their financial valuation is dictated entirely by investor sentiment and clinical milestone progress.